Rebekah Jordan sat down with Lynn Durham, CEO & founder of STALICLA, to discuss STALICLA’s recent partnership with Evgen Pharma that aims bring a therapeutic option to currently underserved patients with neurodevelopmental disorders (NDDs).
Key insights:
- STALICLA is acquiring the licensing of SFX-01 from Evgen Pharma, with aims to push the frontier of precision medicine further into precision NDDs, to enable the targeting of patient groups most likely to benefit from SFX‐01.
- The DEPI platform – from STALICLA - identified two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with tailored treatments for each.
- STALICLA identified SFX-01 as the best treatment candidate for its second subgroup of patients with Autism Spectrum Disorder.
Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This contributes to drug development failure by diluting true responders in a population of patients with heterogeneous biology.